Table 1.
Blood pressure, heart rate and metabolic parameters
| |
Total cholesterol (mmol/l) |
Fasting blood glucose (mmol/l) |
Change in body weight (%) |
Systolic BP (mmHg) |
Heart rate (beats/min) |
|---|---|---|---|---|---|
| Diabetic ApoE−/− | |||||
| Vehicle (n = 8) |
29 ± 3*,# |
23 ± 1*,# |
−5,2 ± 0.5*,# |
124 ± 4# |
992 ± 32* |
| Telmisartan (n = 8) |
31 ± 5* |
19 ± 1* |
−6,9 ± 0.3* |
132 ± 9 |
710 ± 91 |
| Telmi + GW9662 (n = 7) |
48 ± 7*‡ |
22 ± 0.5* |
−3.4 ± 0.6* |
124 ± 5 |
887 ± 66* |
| GW9662 (n = 7) |
72 ± 12*,#,‡ |
32 ± 1*,#,‡ |
−12.4 ± 0.6*,#,‡ |
123 ± 7# |
1040 ± 55*,# |
|
Diabetic ApoE/AT1−/− |
|
|
|
|
|
| Vehicle (n = 6) |
15 ± 5* |
12 ± 1* |
12.6 ± 0.7* |
106 ± 2 |
884 ± 70 |
| GW9662 (n = 6) |
17 ± 3* |
19 ± 2*,# |
−5.9 ± 0.9*,# |
106 ± 4 |
772 ± 38 |
|
Non-diabetic ApoE−/− |
|
|
|
|
|
| Vehicle (n = 8) |
20 ± 2 |
5 ± 0.2 |
46 ± 0.8 |
123 ± 3 |
649 ± 38 |
| Telmisartan (n = 8) |
21 ± 3 |
5 ± 0.4 |
40 ± 0.3 |
118 ± 4 |
727 ± 21 |
| Telmi + GW9662 (n = 8) |
22 ± 2 |
5 ± 0.3 |
42 ± 0.5 |
125 ± 4 |
708 ± 42 |
| GW9662 (n = 8) |
18 ± 1 |
4 ± 0.4 |
48 ± 0.3 |
131 ± 3 |
695 ± 13 |
|
Non-diabetic ApoE/AT1−/− |
|
|
|
|
|
| Vehicle (n = 6) |
8 ± 3 |
5 ± 1 |
47 ± 0.6 |
102 ± 5* |
742 ± 46 |
| GW9662 (n = 6) | 8 ± 3 | 4 ± 1 | 50 ± 0.5 | 105 ± 5* | 679 ± 50 |
To determine cardio-metabolic effects systolic BP, heart rate, fasting blood glucose levels, change in body weight and total cholesterol levels were assessed in vehicle treated diabetic and non-diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice. *P < 0.05 vs. non-diabetic groups. #p < 0.05 vs. corresponding diabetic ApoE−/−/AT1R−/−. ‡P < 0.05 vs. vehicle treated diabetic ApoE−/−, n = 6-8 per group.